Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
1.450
-0.050 (-3.33%)
At close: Dec 17, 2025
113.24%
Market Cap81.46M
Revenue (ttm)154.67K
Net Income (ttm)-14.26M
Shares Out56.18M
EPS (ttm)-0.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,000
Average Volume39,278
Open1.500
Previous Close1.500
Day's Range1.450 - 1.500
52-Week Range0.600 - 2.800
Betan/a
RSI38.84
Earnings DateDec 12, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Employees 1
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.